The effects of vitamin D and evening primrose oil co-supplementation on lipid profiles and biomarkers of oxidative stress in vitamin D-deficient women with polycystic ovary syndrome: A randomized, double-blind, placebo-controlled trial.

What Was Tested

The paper reports a study of Vitamin D, K2, Magnesium and Zinc, published as a randomized controlled trial.

The current study was performed to evaluate the effects of vitamin D plus EPO supplementation on lipid profiles and biomarkers of oxidative stress in vitamin D-deficient women with PCOS.

Who Took Part

The age groups tagged for this paper are young adults and adults, women only.

This randomized, double-blind, placebo-controlled trial was performed among 60 vitamin D-deficient women with PCOS.

How the Study Was Run

In design terms this was a randomized, double-blind and placebo-controlled study.

Random assignment meant chance, not the researchers, decided who got Vitamin D, K2, Magnesium and Zinc and who got the comparison, which limits bias.

As a double-blind Vitamin D, K2, Magnesium and Zinc study, the assignments were hidden from both participants and investigators until the end.

Some participants received a placebo instead of Vitamin D, K2, Magnesium and Zinc, giving a reference point.

What Was Measured

The subject headings attached to it are Biomarkers, Cholecalciferol, Cholesterol, HDL, Cholesterol, VLDL, Dietary Supplements, Glutathione and Hypolipidemic Agents.

The authors tagged it with the keywords Lipid profiles, oxidative stress, polycystic ovary syndrome and supplementation.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Vitamin D, K2, Magnesium and Zinc.

Its findings take up roughly 2 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2018 (Endocrine research), a journal based in England.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.